Form 4: Rani Therapeutics Director Amends Stock Option Exercise Prices

Rani Therapeutics director Maulik Nanavaty amended the exercise prices of several stock options on December 16, 2024.

Summary

• On December 16, 2024, Maulik Nanavaty, a director at Rani Therapeutics, amended the exercise prices of several stock options.
• The exercise price of 101,276 stock options was increased from $2.84 to $4.11 per share.
• Additionally, the exercise price of 15,423 stock options was increased from $2.84 to $9.44 per share.
• There were no changes to the expiration dates or vesting schedules of these options.
• The options vest monthly over three years from June 17, 2021.

Sentiment

Score: 5

Explanation: The document is a routine SEC filing detailing changes in stock option exercise prices, which is neither positive nor negative in itself. It's a neutral event.

Industry Context

This is a standard SEC Form 4 filing related to changes in beneficial ownership of securities by a company director, which is common in the biotech industry where stock options are a significant part of compensation.

Comparison to Industry Standards

• Stock option grants and amendments are a common practice in the biotech industry, particularly for directors and executives.
• The specific exercise prices and vesting schedules are company-specific and depend on the company's valuation and compensation policies.
• Companies like Amgen, Gilead, and Regeneron also use stock options as part of their compensation packages, but the specific terms vary widely.

Stakeholder Impact

• The change in stock option exercise prices may impact the potential future value of the options for the director.
• This filing provides transparency to shareholders regarding the director's holdings and compensation.

Key Dates

Keywords

stock options, exercise price, Rani Therapeutics, director, Maulik Nanavaty, amendment, vesting